Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03169816 · ClinicalTrials.gov registry record · Phase 2
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT03169816 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 60 participants.
The verdict
NCT03169816, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or placebo (N = 20) with weekly therapy.
Interventions
- DRUG Placebo
- DRUG Lorcaserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03169816
The ClinicalTrials.gov registry entry for NCT03169816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03169816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03169816 about?
NCT03169816 is a clinical study titled "Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder". This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to ad...
What is the current status of trial NCT03169816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-05-25. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03169816?
The interventions under investigation include: Placebo (DRUG), Lorcaserin (DRUG).
Who is sponsoring clinical trial NCT03169816?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.